Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the ...

The U.S. surgeon general advised earlier this month that alcohol is a leading preventable cause of cancer, presenting ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

In the last three months, 15 analysts have published ratings on AbbVie ABBV, offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best beginner stocks to buy in 2025. On December 12, Tom Lee, Fundstrat Global Advisors managing ...